MedTrace Logo

Long-Term Follow-up Safety Study of Human Central Nervous System Stem Cells in Subjects With Geographic Atrophy of Age-Related Macular Degeneration

NCT02137915 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 8

Last updated 2016-06-02

No results posted yet for this study

Summary

This study is being done to determine the long-term safety and possible benefits of transplanted Human Central Nervous System Stem Cells (HuCNS-SC) for patients with Geographic Atrophy of Age-Related Macular Degeneration. This long-term follow-up study is limited to those individuals who received a transplant of HuCNS-SC cells into one of their eyes as part of the CL-N01-AMD study. No additional study product will be given in this 4-year long-term follow-up study.

Conditions

Interventions

BIOLOGICAL

Human Central Nervous System Stem Cells

Sponsors & Collaborators

  • StemCells, Inc.

    lead INDUSTRY

Principal Investigators

  • David Birch, Ph.D. · Principal Investigator

Eligibility

Min Age
51 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-04-30
Primary Completion
2016-05-31
Completion
2016-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02137915 on ClinicalTrials.gov